← Return to Any of you heard about the inhibitor RMC-7977?

Discussion

Any of you heard about the inhibitor RMC-7977?

Pancreatic Cancer | Last Active: Mar 28 12:50pm | Replies (17)
Comment receiving replies
@stageivsurvivor

There are two trials that are unique in that they are “pan” KRAS targeted therapies. They have the capability of targeting all KRAS variants, not just a specific one. Revolution Medicine’s RMC-6236 has some limited positions open. It is a phase Ia/Ib dose escalation study. This trial filled fast. There are some limited spaces open.
https://classic.clinicaltrials.gov/ct2/show/NCT05379985
Another trial drug that also is a “pan” KRAS targeted therapy is RSC-1255 made by Rascal Therapeutics. This is in a phase Ia/Ib dose escalation phase and recruiting.
https://classic.clinicaltrials.gov/ct2/show/NCT04678648
Both of these drugs act upstream of the KRAS variants by interrupting the cell signaling pathway at the RAS gene one level above. By blocking the cell signaling pathway there, all variants below it would be prevented from receiving a signal to continue growth and proliferation. As a result, the cell enters apoptosis (programmed cell death) and dies.

Jump to this post

Replies to "There are two trials that are unique in that they are “pan” KRAS targeted therapies. They..."
bluesky05 | @bluesky05 | Mar 28 12:50pm

I'm having difficulty reaching anyone at RasCal Therapeutics re RSC-1255. I have been offered a slot in the RSC-101 trial but it is unclear from the published paper whether the Q61 codon was included in the "pan KRAS" targets. If Q61 was not included, is it still worth considering this trial?

Also, since RasCal posts virtually no information on its website and multiple searches about the company have been unsuccessful, are these red flags?

VIEW AND REPLY